Programa de Doctorado en Salud Pública, Universidad de Chile, Santiago, Chile; Escuela de Salud Pública, Universidad de Chile, Santiago, Chile; Facultad de Odontología, Universidad de Chile, Santiago, Chile.
Facultad de Odontología, Universidad de Chile, Santiago, Chile.
Value Health Reg Issues. 2022 Sep;31:81-92. doi: 10.1016/j.vhri.2022.02.005. Epub 2022 May 11.
In Chile, > 900,000 people with type 2 diabetes mellitus (DM2) are controlled in the Cardiovascular Health Program (PSCV). Even though the PSCV includes a set of interventions for the control of patients with DM2, the results are still insufficient, generating a high human, economic, and social cost. This study aimed to identify and select new health technologies for the control of patients with DM2 not currently incorporated into the PSCV to be proposed as candidates for an economic evaluation in the Chilean context.
For the identification of new health technologies, consultations with key informants and an umbrella review of updated scientific evidence were used as sources of information. In a second step, selection among those technologies was conducted based on the effectiveness of the intervention, target population, nature of the intervention, and international evidence of cost-effectiveness antecedents.
Key informants identified 12 candidate health technologies not currently incorporated into the PSCV. From the umbrella review, an additional 9 health technologies were identified that were not identified by the key informants. Of the 21 new health technologies identified, finally 8 health technologies were selected (structured group education, pedometer use, periodontal treatment, cognitive-behavioral therapy, telemonitoring, sitagliptin, canagliflozin, and insulin degludec).
The health technologies detected have a high potential to be studied through economic evaluations that allow guiding decision making around improving the health outcomes of patients with DM2 in Chile.
在智利,有超过 90 万名 2 型糖尿病(DM2)患者被纳入心血管健康计划(PSCV)进行管理。尽管 PSCV 包含了一系列针对 DM2 患者控制的干预措施,但结果仍然不尽如人意,导致了高昂的人力、经济和社会成本。本研究旨在确定和选择目前未纳入 PSCV 的用于控制 DM2 患者的新医疗技术,作为在智利进行经济评估的候选技术。
为了确定新的医疗技术,我们利用关键信息提供者的咨询意见和对最新科学证据的伞式综述作为信息来源。在第二步中,根据干预措施的有效性、目标人群、干预措施的性质以及国际成本效益证据,对这些技术进行选择。
关键信息提供者确定了 12 种目前未纳入 PSCV 的候选医疗技术。通过伞式综述,又确定了 9 种关键信息提供者未识别的医疗技术。在确定的 21 种新医疗技术中,最终选择了 8 种医疗技术(结构化团体教育、计步器使用、牙周治疗、认知行为疗法、远程监测、西格列汀、卡格列净和德谷胰岛素)。
这些被发现的医疗技术具有通过经济评估进行研究的巨大潜力,这有助于指导决策,以改善智利 DM2 患者的健康结果。